Skip to main content
. Author manuscript; available in PMC: 2008 Oct 7.
Published in final edited form as: Mol Cancer Ther. 2007 Aug;6(8):2188–2197. doi: 10.1158/1535-7163.MCT-07-0235

Figure 5. Rapamycin inhibits mTOR activity in tumor endothelial cells, but does not alter microvessel density.

Figure 5

A/B. Representative sections (400X, bar 50μM) are shown that were immunohistochemically stained for phosphorylated Ribosomal Protein S6 (serine 235/236) in primary tumors collected from mice treated with either vehicle (A) or rapamycin (B) for 32 days. Arrows identify vascular endothelial cells. C/D. Representative sections (200X, bar 50μM) are shown that were immunohistochemically stained for CD31 in primary tumors collected from mice treated with either vehicle (C) or rapamycin (D) for 32 days.